Principle Wealth Partners LLC Purchases Shares of 20,714 CVS Health Corporation $CVS

Principle Wealth Partners LLC purchased a new stake in shares of CVS Health Corporation (NYSE:CVS - Free Report) in the second quarter, according to the company in its most recent filing with the SEC. The firm purchased 20,714 shares of the pharmacy operator's stock, valued at approximately $2,143,000.

Several other institutional investors also recently modified their holdings of CVS. UP Strategic Wealth Investment Advisors LLC purchased a new stake in CVS Health in the second quarter valued at approximately $243,000. Focused Wealth Management Inc purchased a new position in CVS Health in the 2nd quarter worth approximately $207,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in shares of CVS Health in the 2nd quarter worth $322,653,000. Beverly Hills Private Wealth LLC bought a new position in shares of CVS Health in the 2nd quarter worth $351,000. Finally, OneDigital Investment Advisors LLC purchased a new stake in shares of CVS Health during the 2nd quarter valued at $16,515,000. 80.66% of the stock is currently owned by institutional investors.

CVS Health Price Performance

CVS stock opened at $93.99 on Tuesday. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.66 and a current ratio of 0.87. CVS Health Corporation has a 52 week low of $69.40 and a 52 week high of $110.68. The firm's fifty day moving average is $102.46 and its 200 day moving average is $88.41. The firm has a market cap of $120.21 billion, a P/E ratio of 24.87, a P/E/G ratio of 0.93 and a beta of 0.61.

CVS Health (NYSE:CVS - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share for the quarter, topping the consensus estimate of $1.87 by $0.71. CVS Health had a net margin of 1.18% and a return on equity of 13.12%. The business had revenue of $106.10 billion during the quarter, compared to the consensus estimate of $100.03 billion. During the same period in the previous year, the firm posted $1.81 earnings per share. The firm's revenue for the quarter was up 7.3% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. Research analysts predict that CVS Health Corporation will post 8.02 earnings per share for the current year.

CVS Health Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 23rd were paid a $0.665 dividend. This represents a $2.66 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date of this dividend was Thursday, July 23rd. CVS Health's payout ratio is 70.37%.

Insiders Place Their Bets

In related news, Director Larry Robbins sold 370,462 shares of the stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $93.45, for a total transaction of $34,619,673.90. Following the completion of the sale, the director directly owned 4,824,799 shares in the company, valued at $450,877,466.55. This represents a 7.13% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.85% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on CVS. HSBC reiterated a "hold" rating and issued a $103.00 target price on shares of CVS Health in a research report on Monday, July 6th. Argus raised their price target on CVS Health from $90.00 to $104.00 and gave the company a "buy" rating in a research report on Thursday, May 14th. Deutsche Bank Aktiengesellschaft upped their price objective on CVS Health from $88.00 to $92.00 and gave the stock a "buy" rating in a report on Thursday, May 7th. TD Cowen increased their price objective on CVS Health from $105.00 to $110.00 and gave the company a "buy" rating in a research report on Monday, May 11th. Finally, JPMorgan Chase & Co. raised their price objective on CVS Health from $111.00 to $118.00 and gave the company an "overweight" rating in a report on Wednesday, August 12th. Twenty-two research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $106.75.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source